

Jason P Mendoza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8390669/publications.pdf>

Version: 2024-02-01

16
papers

403
citations

932766

10
h-index

1058022

14
g-index

19
all docs

19
docs citations

19
times ranked

498
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune regulatory CNS-reactive CD8+T cells in experimental autoimmune encephalomyelitis. Journal of Autoimmunity, 2010, 35, 33-44.	3.0	71
2	Neuroantigen-specific CD8+ regulatory T-cell function is deficient during acute exacerbation of multiple sclerosis. Journal of Autoimmunity, 2011, 36, 115-124.	3.0	68
3	The Disease-Ameliorating Function of Autoregulatory CD8 T Cells Is Mediated by Targeting of Encephalitogenic CD4 T Cells in Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2013, 191, 117-126.	0.4	44
4	Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US. Multiple Sclerosis and Related Disorders, 2019, 27, 101-111.	0.9	44
5	CD8+ T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease. PLoS ONE, 2013, 8, e66772.	1.1	33
6	Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex). CNS Drugs, 2021, 35, 743-767.	2.7	30
7	Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study. Clinical Therapeutics, 2018, 40, 2077-2087.	1.1	29
8	Modulation of immune function occurs within hours of therapy initiation for multiple sclerosis. Clinical Immunology, 2013, 147, 105-119.	1.4	21
9	Real-World Safety and Effectiveness of Dimethyl Fumarate in Black or African American Patients with Multiple Sclerosis: 3-Year Results from ESTEEM. Neurology and Therapy, 2020, 9, 483-493.	1.4	20
10	Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study. Advances in Therapy, 2022, 39, 1810-1831.	1.3	16
11	Real-World Safety and Effectiveness of Dimethyl Fumarate in Hispanic or Latino Patients with Multiple Sclerosis: 3-Year Results from ESTEEM. Neurology and Therapy, 2020, 9, 495-504.	1.4	10
12	Multiple Sclerosis Patients Treated With Diroximel Fumarate in the Real-World Setting Have High Rates of Persistence and Adherence. Neurology and Therapy, 2021, 10, 349-360.	1.4	7
13	A pharmacokinetic and biomarker study of delayed-release dimethyl fumarate in subjects with secondary progressive multiple sclerosis: evaluation of cerebrospinal fluid penetration and the effects on exploratory biomarkers. Multiple Sclerosis and Related Disorders, 2021, 51, 102861.	0.9	7
14	Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 51, 102935.	0.9	3
15	OR.60. CNS-specific, Autoreactive CD8+ T Cells Have a Regulatory Role in Autoimmune Demyelination. Clinical Immunology, 2008, 127, S25.	1.4	0
16	Activation Induced Suppressive Ability in Human T Cells Revealed by Flow Cytometric Suppression Assay. Clinical Immunology, 2010, 135, S121.	1.4	0